Publications by authors named "Frederik Novak"
Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-a longitudinal cohort study.
Front Immunol
September 2024
Article Synopsis
- This study investigates how patients with multiple sclerosis (MS) on anti-CD20 therapy respond to multiple doses of the BNT162b2 mRNA COVID-19 vaccine and the incidence of breakthrough infections.
- It found that the percentage of participants with antibodies increased significantly after the fourth vaccine dose, but a majority still experienced breakthrough infections during the study.
- The study concluded that while antibody levels increased post-vaccination, T-cell responses remained stable and were not affected by breakthrough infections.
Background: This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS).
Methods: This is a prospective, double-arm, open-label, multi-center study in Denmark. Participants diagnosed with MS on ocrelizumab therapy >12 months were included ( = 184).
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
J Neurol Neurosurg Psychiatry
November 2023
Article Synopsis
- The study examined breakthrough SARS-CoV-2 infections in multiple sclerosis patients treated with ocrelizumab before getting BNT162b2 mRNA vaccinations.
- A total of 54 MS patients were followed, with 32 (59.3%) testing positive for the virus; however, all cases were mild and manageable.
- Results showed that non-infected participants had significantly higher antibody levels after the third vaccination, indicating a potential need for ongoing vaccine development for better protection in this patient group.
Objective: To examine humoral and cellular response in multiple sclerosis patients on anti-CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination.
Methods: A prospective longitudinal study design from first throughout third vaccination in Danish and American MS centers. All participants were treated with ocrelizumab.
Background: The immunogenicity of COVID-19 vaccine among patients receiving anti-CD20 monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of SARS-CoV-2 immunoglobulin G (IgG) are believed to have a predictive value for immune protection against COVID-19 and is currently a surrogate indicator for vaccine efficacy.
Objective: To determine IgG Abs in anti-CD20 treated patients with multiple sclerosis (MS).
Background: In April 2017, the Central Denmark Region Antibiotic Stewardship Committee issued a directive to reduce the general use of piperacillin-tazobactam and prescribe narrow-spectrum antibiotics for mild and moderate pneumonia. The directive was distributed to all regional hospital clinicians.
Methods: Electronic medical records were used to obtain de-identified details of all antibiotics administered (together with diagnosis codes) to all in-hospital patients (pre-directive and post-directive) in the nine regional hospitals.